TauRx Therapeutics / TauRx Pharmaceuticals Ltd (press release), 2024-03-07: Company press release for the 24-month LUCIDITY data presented at AD/PD 2024; the claimed benefit is derived from comparison with external real-world and meta-analytic controls rather than the randomised control arm.
Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
TauRx Therapeutics / TauRx Pharmaceuticals Ltd (press release), 2024-03-07: Company press release for the 24-month LUCIDITY data presented at AD/PD 2024; the claimed benefit is derived from comparison with external real-world and meta-analytic controls rather than the randomised control arm. Issuer is the product's manufacturer, so this is promotional material, not independent evidence. It states the between-arm primary comparison is against external controls ('closely matched real world data and meta-analytical controls'), i.e. not the randomised control. Reports NfL reduction 'relative to the control group (p=0.0291)' and ADAS-Cog13 difference in the early-disease subgroup (p=0.0308). Same release concedes the control arm also received active drug and that the company was 'surprised to find that the blood concentration of active drug follows an atypical profile'.
